Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 20/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 19/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 19/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.66 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854091 | 0.91 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL854092 | 0.91 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL21547950 | 0.87 | OGFRL1 (0.79) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL17561629 | 0.83 | OGFRL1 (0.72) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL21548084 | 0.79 | OGFRL1 (0.73) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL21547966 | 0.79 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL22114404 | 0.79 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL852919 | 0.79 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL852149 | 0.79 | OGFRL1 (0.73) | OGFRL1OPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL852918 | 0.79 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | OGFRL1 2320/4885OPRM1 5/4885OPRK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.